




1. Bladder cancer, urothelial carcinoma, Ta low grade, s/p post TURBT on 2018/4/10 and 2018/7/3 with no recurrence, status post TURBT on 2018/9/28 with tumor recurrence, status post 6-month TURBT on 2018/10/30 with Ta LG recurrence status post 3-month TURBT on 2018/12/29(patho: chronic cystitis) 2. Left hydronephrosis, post left URS with no gross lesion 3. Coronary arterial disease, 2-vessel disease, status post POBAS to LAD, with non-significant ISR, post POBAS to RCA, under DAPT 4. Gastric ulcer 5. Gastroesophageal reflux disease 6. Hyperlipidemia




1. Acute cholecystitis 2. Follicular B cell lymphoma, grade II, stage IIIA, CD20(+), CD10(+), status post R-Bendamustine(III, C1D0=2015/07/30, C2D0=2015/10/12, C3D0=2015/11/06), in partial remission, status post maintenance Rituximab (C1D1=2016/04/22, C2D1=2016/08/27, C3D1=2016/11/17, C4D1=2017/02/12) 3. Vulvar cancer, squamous cell carcinoma, suspect Bartholin originated, cT3N2bM0, stage IVA, status post definitive CCR T (5500 cGy / 25 fractions, 2015/05/05-2015/06/08, Cisplatin, 40 mg/m², C1D1=2015/05/05, C2D1=2015/05/12, C3D1=2015/05/19, C4D1=2015/05/27, C5D1=2015/06/02) 4. Hypertension for 5 years, on Aprovel and Carvedilol 5. Type 2 diabetes mellitus, on Glimepiride, Metformin, and Levemir 6. Hyperthyroidism, status post partial thyroidectomy about 25 years ago 7. Bilateral non-proliferative diabetic retinopathy 8. History of radiation related enteritis and cystitis




1. Colon cancer, ileocecal valve, KRAS G115E mutant, NRAS wild type, BRAF wild type, mismatch repair proficient (MSS), pT3aN2aM0, status post right hemicolectomy in 2014/07/11, status post adjuvant FOLFOX (XII), with bilateral ovarian and peritoneal metastases, status post A+FOLFIRI (III), status post debulking surgery in 2016/04/01, status post A+FOLFIRI (IV-VIII) during 2016/05/08-2016/08/27, status post oral capecitabine during 2016/09/20-2017/08, complicated with hand-foot-mouth syndrome, status post UFUR during 2017/01-2017/08, progression with peritoneal seeding, status post A+FOLFIRI(X, C1D1=2017/08/30, C10D1=2018/01/31), progression, status post A+FOLFOX(I, C1D1=2018/03/12), status post palliative radiotherapy to L1-S1 spine(2500 cGy in 5fr) during 2018/03/26-03/30, status post A+FOLFOX(II, C2D1=2018/04/11) 2. Mitral valve prolapse, under propanolol, Sigmart 3. Hyponatremia, suspect poor intake related




1. Community acquired pneumonia 2. Hypertension, noted for more than 10 years, under Seika and concor




1. Type I respiratory failure, related to influenza A pneumonia, status post endotracheal tube and mechanical ventilation(2016/10/03-) 2. Acute kidney injury, KDIGO stage I



1. Asthma acute exacerbation. 2. Suspect occult pneumonia. 3. Constipation.



Pregnancy for 36+1 weeks with hypertension



1. Hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer (BCLC) stage A, status post (s/p) S5 segmentectomy with cholecystectomy on 2005/4/27; recurrence as BCLC stage B, status post transarterial chemoembolization (TACE) on 2013/4/2, status post radiofrequency ablation (RFA) on 2013/5/6; recurrence with peritoneal metastases BCLC stage C, status post RFA on 2014/10/23 and laparoscopic intra-abdominal tumor excision on 2015/1/7; complicated with HCC rupture, status post TACE on 2015/4/16; relapsed rupture HCC, status post transarterial embolization on 2015/6/24, status post 1st Y90 selective internal radiation therapy (SIRT) on 2015/07/09, status post second Y90 SIRT on 2015/7/23; in progression, status post TACE(CeloNova trial) on 2015/12/10 (I), on 2016/1/18 (II); in progression on Nexavar(2016/05/31-2017/08), status post TACE (CeloNova trial) on 2016/7/4 (III), on 2016/7/11 (IV) and on 2016/10/17 (V); recurrence as BCLC stage C, status post RFA on 2017/2/3, with recurrence on peritoneal seeding status post mini-laparotomy for peritoneal tumor excision on 2017/08/30 with local recurrence on liver, status post TACE on 2017/11/29, with recurrence at S1, status post stereotactic body radiation therapy(SBRT, 2018/04/03-2018/04/16), with multiple recurrence in the liver and suspect peritoneal metastasis, status post BGB-A317

